XRAY Earnings Prediction
The chart below shows how XRAY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, XRAY sees a +3.33% change in stock price 10 days leading up to the earnings, and a -0.98% change 10 days following the report. On the earnings day itself, the stock moves by -2.43%. This data can give you a slight idea of what to expect for the next quarter's release.
XRAY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
951.00M
0.42%
-3.35%
Gross Margin
52.05%
-0.42%
0.04%
Operating Margin
7.05%
-14.44%
-4.99%
Net Margin
-52.05%
85.30%
12595.12%
EPS
-2.46
-95.24%
12200.00%
No Data Available
XRAY Earnings Analysis
DENTSPLY SIRONA Inc. Corporation (XRAY.O) Earnings Conference Call
Positive
Q3 2024 Revenue Increase: 1. Revenue Growth: DENTSPLY SIRONA reported Q3 2024 revenue of $951 million, reflecting a 1.3% organic sales increase driven by distributor orders in anticipation of ERP deployment.
Operating Cash Flow Increase: 2. Strong Operating Cash Flow: The company generated operating cash flow of $141 million in Q3, marking a 5% increase compared to the prior year, attributed to improved inventory management.
Share Repurchase Update: 3. Share Repurchase Program: DENTSPLY SIRONA completed $100 million in share repurchases during the quarter, contributing to a year-to-date total of $345 million returned to shareholders through buybacks and dividends.
Product Launch Impact: 4. Successful Product Launch: The launch of Primescan 2 in September contributed to mid-single-digit growth in CAD/CAM sales, showcasing the positive impact of innovation on product performance.
User Adoption Growth: 5. Increased User Adoption: The DS Core platform saw over 32,000 unique users by the end of Q3, representing a 20% sequential growth, indicating strong customer engagement and adoption of digital solutions.
Negative
Goodwill Impairment Charge: 1. Goodwill Impairment Charge: DENTSPLY SIRONA recorded a non-cash after-tax charge of approximately $500 million related to goodwill in Q3, primarily affecting the Orthodontic and Implant Solutions segment due to sustained macroeconomic pressures and weakened demand.
Byte Sales Decline: 2. Decline in Byte Sales: The Byte business experienced a 19% sequential decline in sales, contributing to a total of $40 million in revenue for Q3, which was dilutive to adjusted EPS.
2024 Sales Forecast Revision: 3. Revised 2024 Outlook: The company revised its full-year 2024 organic sales forecast to a decline of 2.5% to 3.5%, down from a previous estimate of flat to down 1%, indicating worsening market conditions.
Implants Sales Decline: 4. Decline in Implants Sales: Organic sales in the Orthodontic and Implant Solutions segment fell by 3.9%, with the Byte brand declining 7% year-over-year, reflecting soft demand in the U.S. market.
Customer Sentiment Challenges: 5. Negative Customer Sentiment: A customer survey indicated flat patient traffic in the U.S. and Germany, with declines in Japan and China, alongside a slight decrease in utilization of elective procedures, highlighting ongoing market challenges.
XRAY FAQs
How does XRAY typically perform around its earnings report dates?
Is DENTSPLY SIRONA Inc. (XRAY) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
XRAY Earning Call Sentiment
DENTSPLY SIRONA Inc. (XRAY) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
XRAY.O
-1.06%Positive
The earnings call reflects a mixed performance: positive EPS growth and shareholder returns, but declining margins and sales in key areas like orthodontics. The Q&A highlighted uncertainties, especially around Byte and implant strategies. Despite restructuring efforts, the lack of clear guidance and challenges in major markets like China and Europe weigh on sentiment. Overall, the neutral outlook reflects balanced positive and negative factors, with no strong catalysts for significant stock price movement.
